Anzeige
Mehr »
Login
Mittwoch, 04.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AN1Z | ISIN: SE0000767188 | Ticker-Symbol: 7AL
Frankfurt
04.12.24
21:50 Uhr
0,018 Euro
-0,002
-9,60 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALLIGATOR BIOSCIENCE AB Chart 1 Jahr
5-Tage-Chart
ALLIGATOR BIOSCIENCE AB 5-Tage-Chart
ACCESSWIRE
239 Leser
Artikel bewerten:
(1)

Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024

Finanznachrichten News

LUND, SE / ACCESSWIRE / October 30, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces participation in the following conferences during Q4 2024:

Investors and Partnering Conferences

  • ØU Life Science Investor Conference , October 30, Copenhagen
    Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments and upcoming catalysts to investors at 4.55 pm CET, as well as meet institutional investors during the day.

  • BIO-Europe , November 4-6, Stockholm
    Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, and Johan Giléus, Chief Financial Officer of Alligator Bioscience, will attend the conference to meet investors and potential strategic partners.

  • Jefferies London Healthcare Conference, November 19-21, London
    Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, and Johan Giléus, Chief Financial Officer of Alligator Bioscience, will attend the conference to meet investors and potential strategic partners. The Jefferies London Healthcare Conference is one of the most prominent event in Europe and hosted over 800 healthcare companies, 3,500 attendees, and 7,900 investor and business-to-business meetings in 2023.

  • DNB Nordic Healthcare Conference, November 26, Oslo
    Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, and Johan Giléus, Chief Financial Officer of Alligator Bioscience will attend the conference to meet investors and potential strategic partners. Søren Bregenholt will present the company, its latest developments and upcoming catalysts to investors at 1:30 pm CET.

Medical Conference

  • Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting , November 6-10, Houston

    • Dr Thomas Marron will present preliminary results from the Phase 1 dose escalation trial with candidate ALG.APV-527 in a poster entitled " Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity " on Friday, November 8.

    • Ida Uddbäck, Senior Scientist at Alligator Bioscience, will present a poster entitled "ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces myeloid and T-cell dependent anti-tumor activity and synergizes with PD-1 inhibition" on Saturday, November 9.

    • Dr Karen Geboes will present data from the OPTIMIZE-1 clinical Phase 2 trial with candidate mitazalimab in the poster entitled " CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated efficacy and correlative biomarkers from the OPTIMIZE-1 trial " on Saturday, November 9.

For further information, please contact:

Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00

Johan Giléus, CFO
E-mail: johan.gileus@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime, and novel drug candidates based on the RUBY bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com .

Attachments

Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024

SOURCE: Alligator Bioscience



View the original press release on accesswire.com

© 2024 ACCESSWIRE
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.